The Plaintiffs allege that the manufacturers failed to adequately warn of the risk of hemorrhaging associated with the drug and that the Defendants wrongfully touted Xarelto as a superior alternative to warfarin, a medication that has been on the market for decades to prevent blood clots.
The first status conference in the federal multidistrict litigation over Xarelto’s bleeding risks is scheduled for January 29, 2015 in the Eastern District of Louisiana. The Plaintiffs in the litigation allege that the blood thinner may cause uncontrollable bleeding.
The status conference is scheduled to take place on January 29, 2015 at 9:00 a.m. in the U.S. District Court for the Eastern District of Louisiana (In Re: Xarelto Products Liability Litigation, MDL No. 2592). Xarelto is prescribed to prevent blood clots and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Plaintiffs in the litigation allege that Xarelto, an anticoagulant, caused uncontrollable bleeding for which no coagulant or antidote exists.